Mucinous Tumors of the Ovary: Current Thoughts on Diagnosis and Management
- 29 April 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Oncology Reports
- Vol. 16 (6), 1-9
- https://doi.org/10.1007/s11912-014-0389-x
Abstract
Mucinous tumors of the ovary represent a spectrum of neoplastic disorders, including benign mucinous cystadenoma, pseudomyxoma peritonei, mucinous tumors of low malignant potential (borderline), and invasive mucinous ovarian carcinoma. These tumors are related closely to each other and are distinct from other histologic subtypes of epithelial ovarian neoplasms from a clinical, histologic, and molecular standpoint. A continuum appears to be present from benign to borderline to malignant, which is different from other types of epithelial ovarian cancer. Mutational profiles are also distinct, as KRAS mutations are common, but p53 and BRCA mutations are infrequent. These characteristics lead to specific biologic behavior and guide both clinical management and research efforts in patients with mucinous ovarian tumors.This publication has 63 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroupJournal of Clinical Oncology, 2009
- A serum based analysis of ovarian epithelial tumorigenesisGynecologic Oncology, 2009
- Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker StudiesPLoS Medicine, 2008
- Analysis of Gene Expression in Early-Stage Ovarian CancerClinical Cancer Research, 2008
- Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective studyBMC Cancer, 2008
- Should Pelvic and Para-aortic Lymphadenectomy Be Different Depending on Histological Subtype in Epithelial Ovarian Cancer?Annals of Surgical Oncology, 2007
- A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer familiesFamilial Cancer, 2007
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996